Midazolam Nasal Spray (USL261) Phase 3 Trial Meets Primary Efficacy Endpoint In Patients With Seizure Clusters

Cambridge, UK – April 26, 2017 Proximagen Limited (Proximagen) today announced that its pivotal Phase 3 trial of intranasal midazolam (USL261) for the rescue treatment…

Read More

Proximagen to Become Wholly-Owned Subsidiary of ACOVA

Cambridge, UK – April 20, 2017 Proximagen’s parent company Upsher-Smith Laboratories, Inc. (Upsher-Smith), a business owned by the Evenstad family, today announced an agreement to…

Read More


BIO Convention 2017

Proximagen will be attending the BIO International Convention in San Diego, June 19-22 2017

Read More